NYT Strands Today for February 17 features a zodiac animal theme with festive hints and a clever spangram tying the grid together.
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fusemachines Inc. ("Fusemachines" or the "Company") (NASDAQ:FUSE), a leading provider of enterprise artificial intelligence technologies, proudly announces the launch of the 9th year of its flagship AI Fellowship Program, welcoming a new cohort of 100 fellows from diverse backgrounds and geographies.Now in its ninth year, the AI Fellowship Program continues to advance Fusemachines' mission to democratize AI by expanding access to world-class artificial intelligence education and hands-on training. The 2026 cohort will participate in a hybrid learning experience that combines online instruction through the Fusemachines Online Education platform with immersive onsite exercises designed to reinforce practical, real-world AI application.The program is structured to equip participants with strong foundations in machine learning, generative AI, data science, and applied AI systems, while also developing problem-solving skills through collaborative projects and industry-relevant case studies. The blended format enables broader participation while maintaining the rigor and experiential depth that the Fellowship has become known for.Since its inception in 2017, the Fusemachines AI Fellowship Program has empowered over 1,200 fellows across 12 countries in emerging markets, advancing Fusemachines' mission to make AI education accessible to all while providing an experienced funnel of talent to support FUSE's growth strategy. The program has nurtured a new generation of AI talent, with alumni now contributing across multiple departments at Fusemachines as well as at leading technology companies, innovative startups, research institutions, and public sector organizations worldwide."AI is advancing rapidly across industries and communities, but the opportunity to learn and lead in this field is still far from equal," said Dr. Sameer Maskey, Founder and CEO of Fusemachines. "To build an inclusive AI-powered future, we must ensure that students in underserved communities, from rural ...Full story available on Benzinga.com
Spinach PUFFERZTM delivers a flavorful experience combining high-quality cannabis with a sleek tactile design, enhanced with liquid diamondsSpinach PUFFERZTMSpinach PUFFERZTM Pineapple Coconut (Indica), Spinach PUFFERZTM Sour Blue Razz (Hybrid), Spinach PUFFERZTM Tropical AF (Sativa)TORONTO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos”), an innovative global cannabinoid company, announced today the launch of its newest all-in-one (AIO) vape, Spinach PUFFERZTM. The latest innovation under Cronos’ Spinach® brand brings together high-quality cannabis infused with liquid diamonds in a convenient all-in-one device.Crafted for modern cannabis consumers who value functionality and design, Spinach PUFFERZTM offers a seamless way to enjoy high-quality cannabis vape extracts and bold flavors. Every design element was carefully considered to deliver a differentiated experience. Spinach PUFFERZTM is Cronos' first AIO vape featuring the increasingly popular palm-style hardware. The device boasts a uniquely satisfying squishy grip with a puffy exterior, a dual ceramic coil for maximum flavor and smooth draws, a boost button for temperature control, and a battery meter to indicate when a charge is needed."Our leadership in the Canadian cannabis marketplace is driven by our relentless pursuit of excellence in product quality, innovation, and differentiation,” said Mike Gorenstein, Chairman, President and CEO of Cronos. "We are focused on building brand loyalty with fantastic products, and our newest all-in-one vape is a device that looks, feels, and tastes great. The launch of Spinach PUFFERZTM demonstrates our ability to continuously find new ways to innovate and create new cannabis experiences.”Spinach PUFFERZTM all-in-one 1g vapes will launch in three flavors, each infused with liquid diamonds and delivering 98.1% THC:Spinach PUFFERZTM Sour Blue Razz (Hybrid)Inspired by a strain with Blue CKS x Mendobreath lineage and featuring berry and citrus flavor notesSpinach PUFFERZTM Tropical AF (Sativa)Inspired by a strain with Pink Rozay and White Runtz lineage and featuring tropical and fruity flavor notesSpinach PUFFERZTM Pineapple Coconut (Indica)Inspired by a strain with LA Cush CK and Coco Milk lineage and featuring a combo of fruity and vanilla flavor notes "Our teams have been unwavering in their commitment to elevating our vape portfolio with products and flavors that truly connect with consumers,” said Jeff Jacobson, Chief Growth Officer, Cronos. "We’re incredibly excited to introduce a standout innovation like Spinach PUFFERZTM at a time when the all‐in‐one category is experiencing remarkable momentum. As one of Canada’s leading cannabis vape brands, we’re proud to help shape the category and remain dedicated to delivering memorable products that keep Spinach® top‐of‐mind with cannabis consumers,” Mr. Jacobson added.Available now in Alberta, British Columbia, and Ontario, Spinach PUFFERZTM will be available nationally by April 2026. For more information and product availability, visit https://spinachcannabis.com/. To learn more about Spinach PUFFERZTM and stay up-to-date on Spinach® products, follow @spinachwithfriends on Instagram.About Cronos Group Inc.Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.Forward-looking Statements This press release may contain information that may constitute "forward-looking information” or "forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may”, "will”, "expect”, "plan”, "anticipate”, "intend”, "potential”, "estimate”, "believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about future product availability and rollout timing; market trends and demand in the all-in-one cannabis vape category; brand positioning, growth, and leadership; innovation strategy and execution; and anticipated consumer response to Spinach PUFFERZTM; and the Company’s intention to build an international iconic brand portfolio and develop disruptive intellectual property by advancing cannabis research, technology and product development. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, each of which have been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.For further information, please contact: Media Relations Contact: Emily Whalen Communications Tel: (416) 504-0004 media.relations@thecronosgroup.com Investor Relations Contact:Harrison Aaron Investor Relations Tel: (416) 504-0004 investor.relations@thecronosgroup.comA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1336a52e-140a-459b-b7a1-cb871250d7f6
Mars has long been a cold, barren world in our minds, but what if it was once something entirely different?
AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications NEW YORK, Feb. 17, 2026 /PRNewswire/ – Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (“Actinium” or the “Company”), a pioneer in the development of differentiated targeted radiotherapies, today announced that it will present two abstracts at the American Association for Cancer Research (AACR) Annual [...]
TORONTO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) ("Xtract One” or the "Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced that it will release fiscal 2026 second quarter results after the close of trading on March 4, 2026. Peter Evans, Xtract One CEO and Director, and Karen Hersh, CFO and Corporate Secretary, will host a webcast and conference call at 10:00 a.m. Eastern Time the following day, March 5, 2026, to review financial results for the three months ended January 31, 2026.The webcast and presentation will be accessible on the Company’s website, and the telephone number for the conference call is 844-481-3016 (412-317-1881 for international callers). Management will provide an overview of the annual financial results along with management’s outlook for the business, followed by a question-and-answer period.About Xtract One TechnologiesXtract One Technologies is a leading technology-driven threat detection and security solution leveraging AI to provide seamless and secure patron access control experiences. The Company makes unobtrusive weapons and threat detection systems that are designed to assist facility operators in prioritizing- and delivering improved "Walk-right-In” experiences while enhancing safety. Xtract One's innovative portfolio of AI-powered Gateway solutions excels at allowing facilities to discreetly screen and identify weapons and other threats at points of entry and exit without disrupting the flow of traffic. With solutions built to serve the unique market needs for schools, hospitals, arenas, stadiums, manufacturing, distribution, and other customers, Xtract One is recognized as a market leader delivering the highest security in combination with the best individual experience. For more information, visit www.xtractone.com or connect on Facebook, X, and LinkedIn. About Threat Detection and Security SolutionsXtract One solutions, when properly configured, deployed, and utilized, are designed to help enhance safety and reduce threats. Given the wide range of potential threats in today's world, no threat detection system is 100% effective. Xtract One solutions should be utilized as one element in a multilayered approach to physical security.For further information, please contact:Xtract One Inquiries: info@xtractone.com, http://www.xtractone.com Media Contact: Kristen Aikey, JMG Public Relations, 212-206-1645, kristen@jmgpr.comInvestor Relations: Chris Witty, Darrow Associates, 646-438-9385, cwitty@darrowir.com
Workhuman’s Paul Carty discusses his move from engineering into a product management role. Read more: ‘Ownership and hands-on work drew me to product management’
Former House Speaker Kevin McCarthy joins 'Squawk Box' to discuss the DHS funding fight, midterm election outlook, state of the economy, and more.
JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic”, "we”, "us”, "our”, or the "Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health & Biologicals ("Proliant”), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announced the commercial launch of AlbuFreeTM DX, a recombinant human albumin (rHA) product produced using Dyadic’s proprietary filamentous fungal expression technology.The launch of AlbuFreeTM DX underscores Dyadic’s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the terms of the agreement, Dyadic will receive a share of profits from Proliant’s commercial sales of recombinant human albumin products."This launch is a clear validation of Dyadic’s technology and our commercialization strategy,” said Joe Hazelton, President and Chief Operating Officer of Dyadic. "Recombinant human albumin is a well-understood product with broad adoption in cell culture and life science applications, making it an ideal fit for our platform and partner-driven commercialization model.”Recombinant human albumin is a critical component in cell culture media and other life science applications, where demand is rising for animal-free, scalable, and supply-secure inputs. The launch of AlbuFreeTM DX marks the first major commercial step in Dyadic’s growing portfolio of market-specific proteins and represents an important milestone in converting licensed programs into recurring revenue streams."Proliant has decades of experience producing albumin at global scale and supplying customers through an established worldwide distribution network,” said Chris Detzel, President and Chief Executive Officer of Proliant Health & Biologicals. "AlbuFreeTM DX builds on that foundation by adding a high-quality, animal-free recombinant human albumin to our diagnostic market portfolio, allowing us to meet growing customer demand while maintaining the consistency, reliability, and scale our customers expect. Further expansion of the AlbuFreeTM line is expected later this year with the next version specifically formulated for the cell culture market.”"This milestone demonstrates that Dyadic’s microbial platforms are well-suited for products that can be efficiently integrated into existing manufacturing, quality, and commercial infrastructures,” Hazelton added. "We believe this further reinforces the applicability of Dyadic’s technology for scalable commercialization in large, established markets.”Dyadic continues to advance additional recombinant proteins for cell culture, life science, nutrition, and industrial applications through a combination of internal programs and strategic partnerships.About Dyadic Applied BioSolutionsDyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and DapibusTM expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit www.dyadic.comAbout Proliant Health & BiologicalsProliant Health & Biologicals is a global leader in the production of purified bovine and recombinant proteins, serving life science, diagnostic, nutrition, and medical markets worldwide. With decades of manufacturing expertise, vertically integrated operations, and a global network of distributors and customers, Proliant is recognized for its scale, quality, and reliability in albumin and specialty protein supply. For more information about AlbuFreeTM DX and Proliant please visit phb1.comSafe Harbor Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of Dyadic’s clinical trial and interest in its protein production platforms, Dyadic’s research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) Dyadic’s history of net losses; (ii) market and regulatory acceptance of Dyadic’s microbial protein production platforms and other technologies; (iii) failure to commercialize Dyadic’s microbial protein production platforms or its other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) Dyadic’s capital needs; (vii) changes in global economic and financial conditions; (viii) Dyadic’s reliance on information technology; (ix) Dyadic’s dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) Dyadic’s ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause Dyadic’s actual results to differ from its current expectations, please see the section entitled "Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in Dyadic’s expectations.Media contacts:Dyadic Applied BioSolutions:Ping RawsonChief Financial OfficerPhone: (561) 743-8333Email: ir@dyadic.comProliant Health and Biologicals:Alexis VossEmail: Alexis.voss@phb1.com
In a step towards digitising transport services, the Transport Department is planning to roll out the Vahan portal soon, bringing vehicle-related services under a single online platform.The system is ...
WhatsApp Business could potentially start charging users who want to link more than four devices to the same account in a future update.
A bug in Google Messages is causing severe battery drain and overheating on some devices. Here's a temporary fix while you wait for Google to push an update.
Redmi 10 Power Price in India: Redmi has launched its new smartphone Redmi 10 Power in India. The smartphone was launched along with Redmi 10A, on Wednesday, 20 April in India
The premium Alienware m15 R7 and m17 R5 highlight four new Ryzen-powered systems.
Apple is offering its new firmware update for the MagSafe accessory that promises to give you faster charging for the compatible iPhone models.
System apps with native call-recording functionality remain unaffected.
The OnePlus Nord 2T India launch may take place soon as the moniker has been spotted on the TDRA certification. The OnePlus Nord 2T's camera details have also been leaked. Here are the expected specifications of the device.
The iPhone 16 is likely to be the first Apple device to skip the camera notch.
Garena Free Fire Max redeem codes are 12-digit codes that are region-specific and can be used by players to gain an edge over rivals in every round of the battle royale game.
We are still not sure that no-charger policy will be limited to Narzo 50A Prime or it will be extended to other Realme budget, mid-segment and premium phones
